Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 6/20 | 0.60 |
| ▸ | CDK8 | P49336 | 4/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GRK2 | P25098 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444310 | 0.92 | RAF1 (0.60) | RAF1CDK8MAPTALDH1A1MEN1 | |
| SCHEMBL5636194 | 0.92 | RAF1 (0.64) | RAF1CDK8RETMEN1KMT2A | |
| SCHEMBL4442586 | 0.90 | RET (0.58) | RAF1CDK8RETMAPTALDH1A1 | |
| SCHEMBL6031235 | 0.88 | RAF1 (0.66) | RAF1CDK8RETMAPTLMNA | |
| SCHEMBL5636169 | 0.85 | RAF1 (0.65) | RAF1CDK8RETALDH1A1MEN1 | |
| SCHEMBL5634693 | 0.82 | RET (0.61) | RAF1CDK8RETMEN1KMT2A | |
| SCHEMBL16628062 | 0.81 | RAF1 (0.76) | RAF1CDK8RETMEN1KMT2A | |
| SCHEMBL6031038 | 0.81 | RAF1 (0.67) | RAF1CDK8RETALDH1A1MEN1 | |
| SCHEMBL4445772 | 0.81 | CDK8 (0.56) | RAF1CDK8RETMAPTALDH1A1 | |
| SCHEMBL4442139 | 0.81 | CDK8 (0.54) | RAF1CDK8RETMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| EP-1531817-B1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1531817-B1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERK PATENT GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | ARAF, BRAF, RAF1 | RAF1 3/4885CDK8 666/4885RET 106/4885 |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | BRAF, RAF1, ARAF | RAF1 2/4885CDK8 270/4885RET 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.